2012
DOI: 10.1111/j.1365-4632.2011.05014.x
|View full text |Cite
|
Sign up to set email alerts
|

Parotid tuberculosis: a forgotten suspicion (a case report and literature review)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0
3

Year Published

2014
2014
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 14 publications
(10 citation statements)
references
References 28 publications
0
7
0
3
Order By: Relevance
“…Some granulomatous diseases such as tuberculosis and leprosy can cause ulcerative lesions in the oral cavity [ 23 , 56 , 57 ]. The World Health Organization (WHO) has estimated 9.4 million incident cases and 11.1 million prevalent cases of TB globally [ 23 , 57 ]. Tuberculosis rarely affects oral mucosa, roughly 1.4% of all TB cases with a male to female ratio of 4 : 1 [ 23 ].…”
Section: Resultsmentioning
confidence: 99%
“…Some granulomatous diseases such as tuberculosis and leprosy can cause ulcerative lesions in the oral cavity [ 23 , 56 , 57 ]. The World Health Organization (WHO) has estimated 9.4 million incident cases and 11.1 million prevalent cases of TB globally [ 23 , 57 ]. Tuberculosis rarely affects oral mucosa, roughly 1.4% of all TB cases with a male to female ratio of 4 : 1 [ 23 ].…”
Section: Resultsmentioning
confidence: 99%
“…Salivary gland enlargement usually presents as part of a characteristic symptom complex, however salivary gland changes have been reported in the absence of systemic symptoms. [77]…”
Section: Resultsmentioning
confidence: 99%
“…Parotid tuberculosis falls into the category III, and therefore the medication plan adopted is 2RHEZ/4RH. It combines an initial 2-month phase based on 4 so-called first-line antibacterial molecules (RHEZ): rifampicin; isoniazid; ethambutol, pyrazinamide; followed by a 4-month consolidation phase combining (RH) Rifampicin and Isoniazid [8,9]. Direct supervision of medication intake is performed during the initial phase of treatment, with bio clinical and/or radiological monitoring of efficiency and tolerance to antibacterial agents throughout the duration of therapeutic compliance.…”
Section: Discussionmentioning
confidence: 99%